MeSH term
Frequency | Condition_Probility | Adult | 31 | 0.0 |
Aged | 54 | 0.0 |
Aged, 80 and over | 26 | 0.0 |
Alleles | 21 | 0.0 |
Alzheimer Disease/*genetics | 23 | 7.0 |
Apolipoproteins E/genetics | 24 | 7.0 |
DNA/genetics | 3 | 0.0 |
Female | 68 | 0.0 |
Gene Frequency | 25 | 0.0 |
Genotype | 38 | 0.0 |
Humans | 141 | 0.0 |
Male | 72 | 0.0 |
Middle Aged | 46 | 0.0 |
Polymorphism, Genetic | 12 | 0.0 |
Research Support, Non-U.S. Gov't | 75 | 0.0 |
alpha-Macroglobulins/*genetics | 41 | 82.0 |
Adolescent | 13 | 0.0 |
Base Sequence | 11 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Chi-Square Distribution | 4 | 0.0 |
Child | 9 | 0.0 |
Child, Preschool | 5 | 0.0 |
Chronic Disease | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Comparative Study | 25 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
Mutation | 5 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Prognosis | 2 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Age of Onset | 12 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Exons | 4 | 0.0 |
Hungary | 2 | 3.0 |
Reference Values | 6 | 0.0 |
Age Distribution | 2 | 0.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Neuroblastoma | 2 | 1.0 |
Protein Binding | 3 | 0.0 |
Genetic Predisposition to Disease | 9 | 0.0 |
Germany | 2 | 0.0 |
LDL-Receptor Related Protein 1 | 4 | 3.0 |
Linkage (Genetics) | 2 | 0.0 |
*Polymorphism, Genetic | 21 | 0.0 |
Receptors, Immunologic/*genetics | 3 | 2.0 |
Risk Factors | 13 | 0.0 |
Age Factors | 4 | 0.0 |
Sex Factors | 5 | 0.0 |
Gene Deletion | 7 | 0.0 |
Gene Frequency/genetics | 4 | 0.0 |
Polymorphism, Genetic/genetics | 5 | 0.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
Cell Line | 2 | 0.0 |
Blood Cell Count | 2 | 0.0 |
Inflammation | 2 | 0.0 |
Alzheimer Disease/epidemiology/*genetics | 3 | 5.0 |
Odds Ratio | 7 | 0.0 |
Italy | 2 | 0.0 |
Animals | 16 | 0.0 |
Mice | 7 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Amyloid beta-Protein Precursor/genetics | 3 | 6.0 |
Chromosome Mapping | 11 | 0.0 |
Chromosomes, Human, Pair 12/genetics | 4 | 4.0 |
Gene Expression | 2 | 0.0 |
Genetic Markers | 6 | 0.0 |
Membrane Proteins/genetics | 3 | 0.0 |
alpha-Macroglobulins/genetics | 5 | 38.0 |
Sequence Deletion | 4 | 0.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Alzheimer Disease/genetics | 2 | 4.0 |
Apolipoproteins E/*genetics | 2 | 0.0 |
European Continental Ancestry Group | 6 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Alzheimer Disease/*genetics/pathology | 3 | 9.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
*Gene Deletion | 3 | 0.0 |
Senile Plaques/pathology | 3 | 8.0 |
Prospective Studies | 4 | 0.0 |
Parkinson Disease/*genetics | 3 | 3.0 |
Alzheimer Disease/*genetics/*physiopathology | 2 | 25.0 |
Japan | 3 | 0.0 |
*Chromosomes, Human, Pair 12 | 7 | 2.0 |
*Linkage (Genetics) | 4 | 0.0 |
Chromosomes, Human, Pair 12 | 4 | 2.0 |
DNA Primers | 3 | 0.0 |
Introns/genetics | 2 | 0.0 |
China/ethnology | 2 | 1.0 |
Heterozygote Detection | 2 | 0.0 |
Administration, Inhalation | 2 | 1.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
Fluoroimmunoassay | 2 | 4.0 |
Immunoblotting | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Isoleucine/genetics | 2 | 7.0 |
Logistic Models | 3 | 0.0 |
Valine/genetics | 2 | 2.0 |
Family | 2 | 0.0 |
Genetic Screening | 3 | 0.0 |
Lod Score | 3 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Asthma/*physiopathology | 2 | 7.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
alpha-Macroglobulins/analysis | 5 | 12.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/genetics | 2 | 6.0 |
Phenotype | 13 | 0.0 |
Species Specificity | 3 | 0.0 |
alpha-Macroglobulins/*metabolism | 3 | 9.0 |
Leukocyte Count | 2 | 0.0 |
alpha 1-Antitrypsin/analysis | 2 | 2.0 |
*Gene Frequency | 2 | 0.0 |
Italy/epidemiology | 2 | 0.0 |
Acute Disease | 2 | 0.0 |
Bolivia/epidemiology | 2 | 50.0 |
C-Reactive Protein/*analysis | 2 | 0.0 |
Infant | 3 | 0.0 |
alpha-Macroglobulins/*analysis | 6 | 27.0 |
alpha-Macroglobulins/*physiology | 2 | 66.0 |
English Abstract | 3 | 0.0 |
Pregnancy | 2 | 0.0 |
Immunoglobulin A/*genetics | 3 | 42.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Risk | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Chromosome Banding | 2 | 0.0 |
DNA Probes | 5 | 0.0 |
Blotting, Southern | 4 | 0.0 |
Amyloid beta-Protein/metabolism | 2 | 3.0 |
*Genes, Structural | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
China | 3 | 0.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Immunoglobulin Allotypes/*genetics | 5 | 22.0 |
Acute-Phase Proteins/*analysis | 2 | 2.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Permeability | 2 | 1.0 |
Pulmonary Alveoli/*metabolism | 2 | 14.0 |
Alpha-Globulins/analysis | 2 | 22.0 |
Ceruloplasmin/analysis | 2 | 6.0 |
Irrigation | 2 | 3.0 |
Blood Proteins/analysis | 3 | 1.0 |
Europe | 2 | 0.0 |
Immunoglobulin Allotypes/genetics/*immunology | 2 | 100.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Immunoglobulins/analysis | 4 | 1.0 |
Haplotypes | 2 | 0.0 |
Immunoglobulins, Heavy-Chain/*genetics | 3 | 2.0 |
DNA/analysis | 2 | 0.0 |
Blood Proteins/*analysis | 3 | 2.0 |
*Genetic Markers | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Acute-Phase Proteins/blood | 2 | 40.0 |
Environmental Exposure | 2 | 1.0 |
Immunity/*drug effects | 2 | 14.0 |
Immunoglobulins/metabolism | 4 | 3.0 |
Muramidase/blood | 2 | 14.0 |
Acute-Phase Proteins/*blood | 2 | 28.0 |
Immunoglobulins/*analysis | 3 | 3.0 |
Saliva/enzymology/immunology | 2 | 100.0 |
Immunoelectrophoresis | 2 | 0.0 |
Muramidase/metabolism | 2 | 6.0 |
alpha 1-Antitrypsin/metabolism | 4 | 8.0 |
alpha-Macroglobulins/metabolism | 3 | 6.0 |
Fibrinogen/metabolism | 2 | 0.0 |
Chromosomes, Human, 6-12 and X | 2 | 4.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Immunoglobulin Allotypes/genetics | 2 | 11.0 |
Blood Donors | 2 | 0.0 |
Immunoglobulin Allotypes/*analysis/genetics | 2 | 66.0 |
Immunoglobulin G/*analysis | 2 | 2.0 |
Immunoglobulin G/*genetics | 2 | 8.0 |
Immunoglobulin Allotypes/*analysis | 3 | 75.0 |
Antigen-Antibody Complex/*metabolism | 2 | 2.0 |
Spain | 2 | 0.0 |
*Immunoglobulin Allotypes | 3 | 37.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Continental Population Groups | 2 | 1.0 |
*Immunoglobulin A | 2 | 14.0 |
tau Proteins/genetics | 2 | 28.0 |
